Alector licenses AL050 to Genentech for $100M upfront

Alector has entered an exclusive global licensing agreement with Genentech for AL050, an investigational enzyme replacement therapy targeting Parkinson’s and other neurodegenerative diseases, receiving a $100 million upfront payment and eligibility for up to $1.17 billion in milestone payments. Genentech will take over development, regulatory, manufacturing, and commercialization, while Alector retains ownership of its brain-delivery platform and expects the deal to extend its cash runway into 2029.

This Wire brief sits within Fusion42's coverage of Biotech.